Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glycerol→

Glycerol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
56-81-5
Molecular formula
C3H8O3
Molecular weight
92.09 g/mol
Drug class
Hyperosmotic laxativeosmotic agent
Mechanism of action
Retains water in the rectum by an osmotic effect and may also mildly irritate the lower bowel, promoting peristalsis and evacuation. Rectal glycerol also has lubricating and stool-softening effects.
Indications / reported uses
  • Short-term relief of occasional constipation with rectal suppository or enema formulations.
  • Other uses, such as reduction of intraocular pressure, are formulation- and route-specific.

Sources: https://www.medicines.org.uk/emc/product/3534/smpc · https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=4694f05b-d927-4e15-9630-a0a1cddb3cbb

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glycerol Environmental Risk Assessment (ERA) (the Glycerol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.